VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. - Wikidata - wikimedia - TriplyDB

VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.

VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.

http://www.wikidata.org/entity/Q33186480

about

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration Animal models of age related macular degeneration Pathogenesis of herpes stromal keratitis--a focus on corneal neovascularization CCR3 and choroidal neovascularization The mouse retina as an angiogenesis model.Sustained delivery of a HIF-1 antagonist for ocular neovascularization.The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment.Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration.Recombinant non-collagenous domain of alpha2(IV) collagen causes involution of choroidal neovascularization by inducing apoptosis.Emerging drugs for diabetic retinopathy.Diabetic retinopathy: current management and experimental therapeutic targets.Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib.Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels.Neutralizing endogenous VEGF following traumatic spinal cord injury modulates microvascular plasticity but not tissue sparing or functional recovery.The alternative complement pathway regulates pathological angiogenesis in the retina Intravitreal itraconazole inhibits laser-induced choroidal neovascularization in rats.Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization.Oxidative stress promotes ocular neovascularization.Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A Low-dose lipopolysaccharide pretreatment suppresses choroidal neovascularization via IL-10 induction.Review of therapeutic advances in diabetic retinopathy.Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future.Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept.Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases.Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis.Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide Gene transfer for neovascular age-related macular degeneration.Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials.Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF.Aflibercept: A Review of Its Use in Diabetic Macular Oedema.A Simple Optical Coherence Tomography Quantification Method for Choroidal Neovascularization Gene Therapies for Neovascular Age-Related Macular Degeneration.Phosphatidylserine (PS) Is Exposed in Choroidal Neovascular Endothelium: PS-Targeting Antibodies Inhibit Choroidal Angiogenesis In Vivo and Ex Vivo IL-17A differentially regulates corneal vascular endothelial growth factor (VEGF)-A and soluble VEGF receptor 1 expression and promotes corneal angiogenesis after herpes simplex virus infection Ocular neovascularisation and excessive vascular permeability.Experimental study on the photodynamic treatment of choroidal neovasculization with nanophthalocyanine photosensitizer.Receptor tyrosine kinase inhibitors AG013764 and AG013711 reduce choroidal neovascularization in rat eye.

P2860

Q26771522-AA671854-21ED-4959-99C0-E9CC3B13272B Q27004686-0D9D4992-F475-4FB0-A03A-2671AFB080EC Q27023951-A360D38F-3835-497E-805E-069EBD020CC1 Q28742748-A0A259C9-9E44-412B-9C08-68F5125B7910 Q30495106-17D1DE0C-2FC4-4F8C-8743-126B39CD6B18 Q30560557-A30141B9-E53C-45DF-8A0C-584DB8F66B28 Q31061150-6D3AC96B-379E-4644-B089-544870822890 Q33212693-4B9800B2-EAFC-4A82-8CE7-ECB077E8FD53 Q33237435-5A2AE845-F96C-4157-8147-127F1BD5075E Q33388498-290E75A3-E73A-4931-B9DB-05963D9EF3C3 Q33403016-0A74F743-A737-478D-B7DF-740C488A106D Q33429798-B5481CE0-D94A-45C1-BCDE-DF40C67E3B8A Q33584304-DD49D505-7D00-4B86-B6AD-890207E8C332 Q33619010-AB26D45D-F943-47B6-A43A-2FE3B15CD0BC Q33775122-DFA5BA40-6DA9-481A-9D47-69153C91EFDD Q33860350-2BB005FF-F1A4-4929-9A62-743E004B0DF6 Q33868764-302CFECF-0293-4868-9B9B-7296F44627E2 Q34000654-4EF55125-D644-403D-8F05-4B0D99DB217E Q34092454-03B09DEF-E5F9-4043-AC05-FF75B52F7A05 Q34311551-82D39AD3-2B2F-4FF7-8C97-F66166947C39 Q34331369-978082BD-8CBC-4F11-A36B-B7B13DDC8BDD Q34339633-8FD6CF42-A9FF-40B6-8A8D-DB18EEA30DE4 Q34475449-E425A11C-0274-48F1-A9DF-DCBDD2D72DDF Q34554380-3D35E3DE-C426-4C1B-BA94-0BBBFF10F1D9 Q34642583-D324CC9C-30B7-458F-938E-3035BC3BB6C8 Q34658699-B8A3C7A4-553E-44DD-A127-C110F0E408FC Q34800330-22AE5349-A654-4093-9482-90F99DDCA379 Q34816580-25B03730-2F36-4C93-B732-9364DAC95543 Q34843778-27C78B2C-C2CD-4DAF-822D-6B91366EB538 Q35024891-05B2BE99-2223-4F3F-9F25-80FE84CCF26E Q35049227-7E4336BB-AFDC-42E7-9AF2-6B69A0BB0BDE Q35191520-EA5E53F7-0FD5-43ED-A3C4-9B2AF9A6D54F Q35657595-FB0131ED-F670-4994-B5CB-E5031CD66950 Q35659330-F4B64862-4D84-408E-A56D-7D4121BB51D8 Q35795572-81D5A2D4-8033-4491-935E-33C6C031B713 Q35830423-784C1DB2-F034-4B7D-A850-5B2239F214ED Q35850771-618161B7-5F60-4D41-95FE-FDDB448B0D35 Q35873752-BD0CC104-84CC-495B-BCCB-9C3536EB841F Q35924097-05D7B700-ED33-4A4F-9C7E-16FC3F958441 Q36016325-FFF558DF-978C-4113-AA36-0DC07E601D94

P2860

VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.

http://www.wikidata.org/entity/Q33186480

description

2003 nî lūn-bûn

@nan

2003 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

VEGF-TRAP(R1R2) suppresses cho ...... of the blood-retinal barrier.

@ast

VEGF-TRAP(R1R2) suppresses cho ...... of the blood-retinal barrier.

@en

type

label

VEGF-TRAP(R1R2) suppresses cho ...... of the blood-retinal barrier.

@ast

VEGF-TRAP(R1R2) suppresses cho ...... of the blood-retinal barrier.

@en

prefLabel

VEGF-TRAP(R1R2) suppresses cho ...... of the blood-retinal barrier.

@ast

VEGF-TRAP(R1R2) suppresses cho ...... of the blood-retinal barrier.

@en

P1433

Q33186480-A2795499-64F6-4B57-B8F7-E11469B38AAA

P1476

Q33186480-8D4E4170-3037-404D-AEC0-0397D1D72966

P2093

Q33186480-48DAB2EE-B99C-45AA-ADE6-478222FDD676

Q33186480-638DDE42-B438-460A-B1EF-91A750CAFB6B

Q33186480-900A6D11-6870-4C51-94E7-E73F531A1142

Q33186480-94ED509A-A736-4A62-8B56-5835AC8011D6

Q33186480-BA9D3BFD-098D-46D9-95FA-5F827792D3C1

Q33186480-BE242B52-C630-4E49-B166-0A4E35FDA3C6

Q33186480-C88D2814-D59F-4D84-B5E6-56EC2B63EC05

Q33186480-EC23D826-93FA-4FB8-80A1-18E5B44B00F6

P304

Q33186480-DB2EB10D-0EC3-4EFA-9480-702EDC5998D6

P31

Q33186480-C370C632-586F-4D20-AEBD-FD59D16F13FA

P356

Q33186480-F5FFE655-5CEE-489E-A9CF-3E81053BB1E9

P433

Q33186480-540DBB3D-CAF5-4461-B4DD-42BD0F3E43CB

P478

Q33186480-56685C9E-DA98-4E34-A0B4-C473B6DB2BB9

P577

Q33186480-06817684-4E3C-46E5-BF09-27F9941F8B85

P698

Q33186480-774702CA-0DD1-4DBE-A2B5-366B33D5EFAA

P921

Q33186480-924EBCE2-4777-47CD-80B5-360CC9BBF462

P356

P1433

Journal of Cellular Physiology

P1476

VEGF-TRAP(R1R2) suppresses cho ...... of the blood-retinal barrier.

@en

P2093

Donna Hylton

http://www.w3.org/2001/XMLSchema#string

John S Rudge

http://www.w3.org/2001/XMLSchema#string

Kyoichi Takahashi

http://www.w3.org/2001/XMLSchema#string

Peter A Campochiaro

http://www.w3.org/2001/XMLSchema#string

Raquel Lima e Silva

http://www.w3.org/2001/XMLSchema#string

Stanley J Wiegand

http://www.w3.org/2001/XMLSchema#string

Yoshitsugu Saishin

http://www.w3.org/2001/XMLSchema#string

Yumiko Saishin

http://www.w3.org/2001/XMLSchema#string

P304

241-248

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCP.10246

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

195

http://www.w3.org/2001/XMLSchema#string

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12652651

http://www.w3.org/2001/XMLSchema#string

P921

neovascularization